Open AccessReview on the Outpatient Treatment for Pelvic Inflammatory Disease, what is the best for Hong Kong?
Author(s) -
Kung SW,
Ng MH
Publication year - 2005
Publication title -
hong kong journal of emergency medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.145
H-Index - 12
eISSN - 2309-5407
pISSN - 1024-9079
DOI - 10.1177/102490790501200306
Subject(s) - medicine , pelvic inflammatory disease , neisseria gonorrhoeae , azithromycin , metronidazole , ceftriaxone , gonorrhea , salpingitis , levofloxacin , infertility , chlamydia trachomatis , cephalosporin , ectopic pregnancy , disease , pelvic pain , antibiotics , gynecology , obstetrics , surgery , pregnancy , immunology , microbiology and biotechnology , genetics , human immunodeficiency virus (hiv) , biology
Pelvic inflammatory disease is an important risk factor for infertility, ectopic pregnancy and chronic pelvic pain. Although the Centers for Disease Control and Prevention published treatment guidelines for pelvic inflammatory disease in 2002, the effectiveness of treatment has been affected by the emergence of quinolone‐resistant Neisseria gonorrhoeae. The prevalence of quinolone‐resistant Neisseria gonorrhoeae is highly variable with time and place. In Hong Kong, quinolone‐resistant Neisseria gonorrhoeae is over 90%, thus ceftriaxone, doxycycline and metronidazole should be the treatment of choice. For patients sensitive to cephalosporins, azithromycin and metronidazole can be considered as alternative treatments.